Back to List View Graph View

Taxane

Taxanes are a class of microtubule-targeting antineoplastic agents used widely in oncology.

Where the papers sit

19 papers from the last 6 months study taxane directly · updated from PubMed 15 Nov 2026

  • Breast Cancer Chemotherapy

    Paclitaxel strategies in breast cancer are moving toward targeted delivery and combination treatment, especially for triple-negative disease. Nanovesicles, lipid nanoparticles, exosomes, solid dispersions with piperine, and αvβ3 targeting seek greater tumor exposure and synergy with quercetin or photothermal therapy. Clinical comparisons weigh anthracycline-containing versus anthracycline-free carboplatin regimens, including BRCA1/2 carriers. Neuropathy prediction remains a parallel effort, with nailfold capillaroscopy proposed for risk stratification.

    8 papers · 42.1%

  • Head and Neck Chemotherapy

    Head and neck cancers are being treated with taxane-carboplatin combinations, often adding cetuximab or chemoradiotherapy around surgery. Neoadjuvant therapy is assessed for clinical and pathological response in locally advanced disease, while liposomal doxorubicin plus nab-paclitaxel is tested in adenoid cystic carcinoma. Patient-derived tongue squamous-cell models extend this work toward individualized drug-response testing. Evidence remains early, with phase II and model-based data rather than a settled regimen.

    3 papers · 15.8%

  • Pancreatic Cancer Treatment

    Pancreatic cancer treatment is centered on nab-paclitaxel combination strategies, including induction with S-1 for locally advanced disease. Nanomedicine work seeks additional drug combinations to improve delivery and antitumor activity in this resistant cancer. Weekly paclitaxel protocols are also moving toward reduced dexamethasone premedication to limit steroid toxicity without increasing early hypersensitivity reactions. Whether lower steroid exposure preserves safety across broader populations remains open.

    3 papers · 15.8%

  • Others — Cancer Therapy and Imaging

    Taxane-related work here spans post-checkpoint gastric cancer therapy, second-line lung cancer treatment, bladder-cancer imaging, and experimental phenylahistin derivatives. Ramucirumab plus taxane is evaluated after nivolumab in HER2-negative advanced gastric cancer, while sotorasib is compared with docetaxel in advanced NSCLC. MRI radiomics aims to define immune states in high-risk bladder cancer, and dual-inhibition compounds remain preclinical. The cluster therefore has no single biological or clinical direction beyond evaluating cancer treatments and response.

    5 papers · 26.3%

PARADIGM SHIFT

Prior immune-checkpoint therapy does not enhance subsequent taxane–ramucirumab efficacy

The study of HER2-negative advanced gastric cancer treated with ramucirumab plus taxane after immune checkpoint inhibitor therapy 42823186Oct and the study of HER2-negative advanced gastric cancer treated with taxane plus ramucirumab after oxaliplatin-based chemotherapy with or without nivolumab 42247598Jun challenge the assumption that prior immune checkpoint inhibition improves the later taxane regimen. The first found no significant progression-free or overall-survival difference according to whether prior ICI treatment produced progressive disease or a better response, despite a 30.4% response rate to the subsequent regimen; the second found nearly identical overall survival in ICI-exposed and ICI-naive patients. Thus, prior ICI exposure or failure should not be presumed to sensitize tumors to subsequent taxane–ramucirumab treatment or to determine its benefit.

taxane chemical structure

Papers

The 19 papers from the last 6 months that study taxane directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Breast Cancer Chemotherapy (8)
  1. Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes. Breast cancer research and treatment · 9 Sept 2026 PMID 42714613
  2. Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer. European journal of cancer (Oxford, England : 1990) · 11 Aug 2026 PMID 42580099
  3. Predicting taxane-induced peripheral neuropathy by nailfold capillaroscopy: The CAPNEU pilot study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 26 Jul 2026 PMID 42503543
  4. Exosomes as Biomimetic Nanoplatforms for Synergistic Targeted Chemotherapy and Photothermal Treatment of Breast Cancer. Journal of biochemical and molecular toxicology · 15 Jun 2026 PMID 42290533
  5. Potentiating Paclitaxel with its Homologous Nanovesicles: A Synergistic Strategy for Triple-Negative Breast Cancer Therapy. ACS applied materials & interfaces · 10 Jun 2026 PMID 42268988
  6. Integrin αvβ3-Targeted SLNs for Co-Delivery of Paclitaxel and Quercetin in Triple-Negative Breast Cancer. ACS applied materials & interfaces · 10 Jun 2026 PMID 42267862
  7. Strain-promoted click chemistry boosts microbubbles for targeted ultrasound imaging and cancer chemotherapy. Acta biomaterialia · 5 Jun 2026 PMID 42248283
  8. Improving Paclitaxel permeation and anticancer efficacy through Soluplus-based solid dispersion with Piperine. Drug development and industrial pharmacy · 20 May 2026 PMID 42160324
Head and Neck Chemotherapy (3)
  1. Neoadjuvant Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab for Locally Advanced Head and Neck Cancer. Anticancer research · 29 Jun 2026 PMID 42373242
  2. Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies. Medical oncology (Northwood, London, England) · 29 Jun 2026 PMID 42371352
  3. Liposomal doxorubicin plus nab-paclitaxel with/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study. Signal transduction and targeted therapy · 12 Jun 2026 PMID 42285940
Pancreatic Cancer Treatment (3)
  1. Reduced-dose dexamethasone premedication for weekly paclitaxel: a retrospective cohort study of early hypersensitivity reactions and steroid-related toxicity. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 29 Jun 2026 PMID 42371187
  2. Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. Signal transduction and targeted therapy · 21 Jun 2026 PMID 42324245
  3. Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 18 Jun 2026 PMID 42312894
Others — Cancer Therapy and Imaging (5)
  1. Clinical Outcomes of Ramucirumab Plus Taxane After Immune Checkpoint Inhibitor Therapy in HER2-negative Advanced Gastric Cancer. Anticancer research · 1 Oct 2026 PMID 42823186
  2. Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel. Cancer · 24 Jun 2026 PMID 42339693
  3. Design, Synthesis, and Evaluation of Antitumor Activity of Novel Phenylahistin Derivatives with Double F-Substitution via Dual Inhibition of Microtubule and P53/BCL-2/BAX Signaling Pathways. Journal of medicinal chemistry · 11 Jun 2026 PMID 42273719
  4. Impact of prior nivolumab on treatment outcomes of taxane plus ramucirumab in advanced gastric cancer. Japanese journal of clinical oncology · 5 Jun 2026 PMID 42247598
  5. Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England. Lung cancer (Amsterdam, Netherlands) · 2 Jun 2026 PMID 42229337

By study type

Clinical trials (2)
  1. Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. Signal transduction and targeted therapy · 21 Jun 2026 PMID 42324245
  2. Liposomal doxorubicin plus nab-paclitaxel with/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study. Signal transduction and targeted therapy · 12 Jun 2026 PMID 42285940
Observational studies and case reports (8)
  1. Clinical Outcomes of Ramucirumab Plus Taxane After Immune Checkpoint Inhibitor Therapy in HER2-negative Advanced Gastric Cancer. Anticancer research · 1 Oct 2026 PMID 42823186
  2. Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes. Breast cancer research and treatment · 9 Sept 2026 PMID 42714613
  3. Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer. European journal of cancer (Oxford, England : 1990) · 11 Aug 2026 PMID 42580099
  4. Predicting taxane-induced peripheral neuropathy by nailfold capillaroscopy: The CAPNEU pilot study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 26 Jul 2026 PMID 42503543
  5. Neoadjuvant Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab for Locally Advanced Head and Neck Cancer. Anticancer research · 29 Jun 2026 PMID 42373242
  6. Reduced-dose dexamethasone premedication for weekly paclitaxel: a retrospective cohort study of early hypersensitivity reactions and steroid-related toxicity. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 29 Jun 2026 PMID 42371187
  7. Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel. Cancer · 24 Jun 2026 PMID 42339693
  8. Impact of prior nivolumab on treatment outcomes of taxane plus ramucirumab in advanced gastric cancer. Japanese journal of clinical oncology · 5 Jun 2026 PMID 42247598
Human data, design not indexed (1)
  1. Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England. Lung cancer (Amsterdam, Netherlands) · 2 Jun 2026 PMID 42229337
Preclinical: animal, cell and lab studies (8)
  1. Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies. Medical oncology (Northwood, London, England) · 29 Jun 2026 PMID 42371352
  2. Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 18 Jun 2026 PMID 42312894
  3. Exosomes as Biomimetic Nanoplatforms for Synergistic Targeted Chemotherapy and Photothermal Treatment of Breast Cancer. Journal of biochemical and molecular toxicology · 15 Jun 2026 PMID 42290533
  4. Design, Synthesis, and Evaluation of Antitumor Activity of Novel Phenylahistin Derivatives with Double F-Substitution via Dual Inhibition of Microtubule and P53/BCL-2/BAX Signaling Pathways. Journal of medicinal chemistry · 11 Jun 2026 PMID 42273719
  5. Potentiating Paclitaxel with its Homologous Nanovesicles: A Synergistic Strategy for Triple-Negative Breast Cancer Therapy. ACS applied materials & interfaces · 10 Jun 2026 PMID 42268988
  6. Integrin αvβ3-Targeted SLNs for Co-Delivery of Paclitaxel and Quercetin in Triple-Negative Breast Cancer. ACS applied materials & interfaces · 10 Jun 2026 PMID 42267862
  7. Strain-promoted click chemistry boosts microbubbles for targeted ultrasound imaging and cancer chemotherapy. Acta biomaterialia · 5 Jun 2026 PMID 42248283
  8. Improving Paclitaxel permeation and anticancer efficacy through Soluplus-based solid dispersion with Piperine. Drug development and industrial pharmacy · 20 May 2026 PMID 42160324